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Summary Neurological deterioration can occur in 13—38% of patients with acute ischemic
stroke due to hemodynamic and non-hemodynamic causes. Several non-hemodynamic mecha-
nisms can lead to ischemic lesion extension and subsequent neurological worsening, including
infections, cerebral edema, hemorrhagic conversion of infarction and metabolic disorders. The
most common hemodynamic causes related to infarct expansion, leading to neurologic deteri-
oration in the setting of acute cerebral ischemia are the following: (i) cardiac complications,
(ii) arterial reocclusion, (iii) intracranial arterial steal phenomenon, and (iv) cerebral microem-
bolization. The present review aims to address the underlying mechanisms and potential clinicalReocclusion
implications of the hemodynamic causes of neurological deterioration in patients with acute
cerebral ischemia. The contribution of neurosonology in detection of changes in cerebral hemo-
dynamics in real-time are also going to be discussed. Finally, potential treatment strategies for
speciﬁc causes of hemodynamic deterioration in acute ischemic stroke patients are reported.
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Early neurological deterioration: prevalence
and deﬁnitions
Early neurological deterioration (END) has been described
as worsening in neurological function during the ﬁrst days
of acute cerebral ischemia (ACI) [1]. The prevalence of END
varies in different studies according to the deﬁnition used
Openfor END detection [1]. An Italian study reported that END
occurred in 20—26% of non-thrombolysed patients present-
ing with acute ischemic stroke (AIS) [2]. END was deﬁned
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Open access under CC BY-NC-ND license.s a decrease of 1 or more points, in the Canadian Neu-
ological Scale (CNS) score from hospital admission to 48 h
fter stroke onset. The investigators of European Cooper-
tive Acute Stroke Study (ECASS) I identiﬁed factors that
otentially predicted or were associated with progression
f stroke and evaluated the inﬂuence of stroke progres-
ion on neurologic worsening. Early progressing stroke (EPS)
as deﬁned as a decrease of ≥2 points in consciousness or
otor power or a decrease of ≥3 points in speech scores
n the Scandinavian Neurological Stroke Scale from hospital
dmission to the 24-h evaluation. END was documented in
7.5% of all patients during the ﬁrst 24 h after inclusion in
s under CC BY-NC-ND license.he study (37% in the placebo group and 38% in the recom-
inant tissue plasminogen activator group) [3]. Grotta et al.
sed the National Institute of Neurological Disorders and
troke (NINDS) rt-PA Stroke Trial database to document the
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revalence of clinical deterioration following improvement
DFI) and of any signiﬁcant clinical deterioration (CD) even
f not preceded by improvement. DFI was deﬁned as any
-point deterioration on the NIH Stroke Scale (NIHSS) score
fter an initial 2-point improvement after treatment. CD was
eﬁned as any 4-point worsening after treatment compared
ith baseline. DFI and CD identiﬁed in 13% and 16% of all
atients, respectively [4]. END was also detected in 19% and
3% of patients hospitalized in general medical wards and
cute stroke units, respectively, according to the ﬁndings of
n Australian [5] and German [6] study, respectively. END
as deﬁned as 1-point and 2-point increase in NIHSS (dur-
ng the ﬁrst three and ﬁve days of ictus respectively) in the
ustralian and German study, respectively.
Recent studies have shown that END is an independent
redictor of poor outcomes in the setting of AIS. More
peciﬁcally, the investigators of SORCan (Stroke Outcomes
esearch Canada) registry have reported that END (deﬁned
s 1-point decrease in CNS) was an independent predictor
f 7-day, 30-day and 1-year case fatality rate in a cohort of
631 patients [7]. Similarly, END was associated with higher
ates of death during hospitalization, longer duration of hos-
italization and lower rates of functional independence in
n Australian study [5].
auses of early neurological deterioration
he causes of END can be classiﬁed into two major
roups: hemodynamic and non hemodynamic [1]. Several
on-hemodynamic mechanisms can lead to ischemic lesion
xtension and subsequent neurological worsening, including
nfections, cerebral edema/increased intracranial pressure,
emorrhagic conversion of infarction and metabolic dis-
rders (hypoxia, hyperglycemia and fever) [1]. The most
ommon hemodynamic causes related to infarct expansion,
eading to END in the setting of ACI are the following: (i) car-
iac complications, (ii) arterial reocclusion, (iii) intracranial
rterial steal phenomenon and (iv) cerebral microemboliza-
ion.
ardiac complications and END
atients with severe disabling strokes are particularly
ulnerable to cardiac complications because stroke can
rovoke disturbances in autonomic and neurohormonal con-
rol and predispose patients to severe cardiac adverse
vents (SCAEs). It is well-known that acute stroke may lead
o a variety of cardiac abnormalities such as myocardial
nfarction, electrocardiographic changes, cardiac arrhyth-
ias, cardiac arrest, stress cardiomyopathy (tako-tsubo
yndrome) and intracardiac thrombus [8]. SCAEs can hin-
er functional recovery and contribute to cardiac morbidity
nd mortality [8]. They are common in the acute period
fter stroke onset (19.0% of all patients experience at least
ne SCAE) and are responsible for 2—6% of the total mor-
ality three months after acute ischemic stroke [9]. The
ain predictors of SCAE are outlined below: history of heartailure, diabetes mellitus, baseline creatinine >115mol/L,
evere stroke, and a long QTc (>450ms in men and >470ms in
omen) or ventricular extrasystoles on ECG, low admission
ystolic blood pressure (<110mmHg) and right insular stroke
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8,9]. Right insular region has been shown to moderate the
utonomic control of the heart and this may partly explain
he potential relationship of right insular stroke with SCAEs.
oreover insular infarction is associated with abnormal car-
iac repolarization and increased risk of vascular mortality
9].
The main mechanisms linking SCAEs with END are outlined
elow: (i) hemodynamic instability/hypotension (which may
n turn worsen the impaired cerebral autoregulation and
urther reduce perfusion in the infracted brain tissue), (ii)
ncreased risk of sudden cardiac death, and (iii) increased
isk of recurrent stroke and systemic embolism. There
s mounting evidence linking extremely low admission BP
evels with adverse early and late functional outcomes
n patients presenting with ACI [10,11]. In addition the
esults of a recent randomized phase III trial showed that
cute antihypertensive therapy causing mild BP reductions
3—6mmHg) during the ﬁrst 7 days of AIS was not related
o better functional outcome or lower rates of cardiovascu-
ar events when compared to placebo. In contrast, stroke
rogression was increased by almost 50% in patients treated
ith antihypertensive therapy in comparison to the placebo
roup [12].
otential therapeutic strategies of END caused by
ardiac complications
he following therapeutic measures may be considered in
atients with END caused by SCAEs:
. Avoiding antihypertensive medications during the ﬁrst
48 h of ACI (unless systolic blood pressure/diastolic blood
pressure > 220/120mmHg).
. Prolonging cardiac monitoring in patients at high risk
for cardiac arrhythmias in order to increase the yield of
timely detection of cardiac arrhythmias and early initia-
tion of appropriate medications (e.g. beta-blockers).
. Avoiding ﬂuid overload in patients with congestive heart
failure.
. Using early anticoagulation (unfractioned heparin) in
patients with intracardiac thrombus.
. Using pressors in patients wih Tako-tsubo syndrome in
order to increase the cardiac output.
rterial reocclusion and END
arly reocclusion may be the most common mechanism of
arly clinical ﬂuctuation and worsening after thrombolytic
herapy and intra-arterial procedures for acute ischemic
troke, leading to poor clinic outcome and higher in-hospital
ortality [13,14]. Thrombolytic therapy has been demon-
trated to be effective in acute stroke by dissolving the
rterial occlusion and reestablishing tissue perfusion. How-
ver, the beneﬁcial effect of tissue plasminogen activator
tPA)-induced recanalization may be eventually hampered
y the occurrence of reocclusion [13,14].
Early reocclusion occurs in 15—34% of AIS patients treated
ith iv-tPA achieving any initial recanalization, account-ng for up 2/3 of deterioration following improvement
13,14]. Reocclusion can be detected in real-time using
ranscranial Doppler (TCD) monitoring [13—16]. Reocclusion
s observed in 17% of patients, who undergo intra-arterial
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thrombolysis based on catheter angiographic surveillance
[17]. Reocclusion can also occur during or after catheter-
based interventions [18]. In particular, the prevalence of
reocclusion occurring during and within an hour after intra-
arterial reperfusion procedures (mechanical thrombectomy,
thromboaspiration, intra-arterial thrombolysis) is 19% and
8%, respectively [18].
Reocclusion in stroke patients appears to occur most
in those with partial initial recanalization. These patients
may be prone to repeated thrombosis and artery-to-artery
reembolization particularly in the setting of a large ves-
sel atherosclerosis [14,19]. Another potential independent
predictor of reocclusion is severe stroke given the fact
that increased stroke severity as reﬂected by higher NIHSS-
scores represents larger thrombus burden [20]. Interestingly,
Rubiera et al. have documented that admission NIHSS-scores
higher than 16 points and severe ipsilateral carotid disease
were independently associated with reocclusion in multi-
variate logistic regression models adjusting for potential
confounders [14]. Finally, arterial reocclusion was related
to lesser neurological improvement during hospitalization
and lower rates of three-month functional independence in
two stroke registries of systemic thrombolysis [14,19].
Early reocclusion can be detected in real-time with con-
tinuous 1-h TCD-monitoring during iv-tPA infusion [13,14]
and our pilot study demonstrated that TCD can detect arte-
rial reocclusion during or within an hour after completion of
intra-arterial procedures [18]. There is also small anecdotal
data indicating that continuous ultrasound surveillance may
provide rapid detection of reocclusion (Fig. 1) as well as
persistent occlusion and assist in subsequent management
decisions including GPIIb-IIIa antagonist administration [21]
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Figure 1 (A) Left M2MCA (middle cerebral artery) occlusion (throm
thrombolysis (MFV = 13 cm/s, high-resistance ﬂow on M-Mode spectru
bolus (TIBI V; MFV = 27 cm/s, low-resistance ﬂow on M-Mode spectrum
tPA-bolus (TIBI V) but high-resistance ﬂow signatures appear on M-M
in Pulsatility Index (from 1.3 in (B) to 1.7), and (D) re-occlusion occ179
r direct thrombin inhibitor administration (such as arga-
roban) [22] in patients with END due to reocclusion.
otential therapeutic strategies of END caused by
rterial reocclusion
he following therapeutic measures may be considered in
atients with END caused by arterial reocclusion:
TCD-monitoring of intracranial vessel patency during the
ﬁrst hours following reperfusion procedures (especially
during the ﬁrst 2 h following tPA-bolus).
Emergent intra-arterial reperfusion procedures
(thrombectomy/thromboaspiration) if reocclusion is
detected.
Continuous 2-h argatroban infusion following standard
intravenous thrombolysis may be a future therapeutic
option for reducing reocclusion.
ntracranial arterial steal phenomenon and END
he Starling resistor model deﬁnes cerebral perfusion pres-
ure as the difference between arterial pressure and venous,
ntracranial, or tissue pressure (whichever is highest) [23].
lood ﬂow occurs due to pressure gradient with blood
ollowing the path of least resistance and ﬂow diversion
eing caused by effective outﬂow differences for the Star-
ing resistors [23]. The concept of blood ﬂow steal in the
erebral circulation is well established [24]. In brain, hemo-
ynamic steal and shunts were documented with angiomas
nd hypervascularized brain tumors [24,25]. Neurological
ymptoms were linked to cerebral blood ﬂow reduction with
bolysis in brain ischemia TIBI II) before the onset of intravenous
m). (B) Complete recanalization was achieved 28min after tPA
), (C) Complete recanalization is sustained at 42min following
ode spectrum, while spectral interrogation reveals an increase
urred at 56min following tPA-bolus (TIBI II).
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Figure 2 Intracranial arterial steal phenomenon during voluntary breath-holding in a patient with acute cerebral ischemia due
to proximal M1MCA occlusion. A decrease in M1MCA MFV (mean ﬂow velocity) is documented during voluntary breath-holding (from
46 cm/s at the beginning to 39 cm/s at the end of breath-holding). A simultaneous substantial ﬂow diversion toward ipsilateral ACA
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panterior cerebral artery) is documented during voluntary breat
reath-holding).
rterio-venous malformations [24] or rare cases of the sub-
lavian steal syndrome [26].
The concept of arterial steal has been evaluated in
eal-time in the setting of ACI. Alexandrov et al. observed
aradoxical decreases in ﬂow velocity during episodes of
ypercapnia in vessels supplying ischemic areas of the brain
t the time of expected velocity increase in nonaffected
essels [27]. Hypercapnia triggered vasodilation more effec-
ively in normal vessels, thus producing arterial blood ﬂow
teal toward the path of least resistance (Fig. 2) [27]. The
emodynamic steal was also documented on CT perfusion
efore and after challenge with acetazolamide (Diamox).
he steal magnitude was linked to severity of neurologi-
al worsening in patients with acute stroke [27,28]. This
ntrancranial steal phenomenon when coupled with END
determined as an increase of >2 points in NIHSS-score) was
ermed ‘‘Reversed Robin Hood Syndrome (RRHS)’’ for an
nalogy with ‘‘rob the poor to feed the rich [27].
Sharma et al. attempted to evaluate RRHS in a
rospective series of patients with severe intracranial
teno-occlusive disease using bilateral TCD-monitoring with
S
t
wlding (from 79 cm/s at the beginning to 105 cm/s at the end of
oluntary breath-holding and acetazolamide-challenged
9mTc-HMPAO (hexamethylpropylene amine oxime) SPECT
29,30]. The magnitude of arterial steal was calculated
sing changes in mean ﬂow velocities (MFVs) during TCD-
onitoring and net deﬁcit in metabolic perfusion after
cetazolamide-challenge on HMPAO-SPECT (Fig. 3). Inter-
stingly, identiﬁcation of intracranial steal phenomenon
n TCD had satisfactory agreement with detection of
nadequate vasodilatory reserve leading to perfusion
eﬁcit on acetazolamide-challenged HMPAO-SPECT. More-
ver, a strong linear correlation was identiﬁed between
ntracranial steal magnitude (%) on TCD [calculated
s [(MFVm−MFVb)/MFVb]× 100, where m=minimum and
= baseline MFVs during the 15- to 30-s period of a total 30 s
f breath-holding] [27] and net perfusion deﬁcit on SPECT
fter Diamox-challenge in patients who exhibited both steal
henomenon on TCD and failed vasodilatory reserve on
PECT (Fig. 4).
Alexandrov et al. conducted a pilot study to investigate
he prevalence of RRHS in a consecutive series of patients
ith ACI. They showed that among 153 patients admitted
Hemodynamic causes of deterioration in acute ischemic stroke
Figure 3 HMPAO SPECT (single-photon emission computed
tomography) imaging after acetazolamide (Diamox) challenge
shows a paradoxical reduction in the left MCA territory perfu-
sion (net perfusion deﬁcit 12.9%) resulting from the Reversed
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nRobin Hood Syndrome in a patients with acute cerebral arterial
ischemia due to left terminal internal carotid artery occlusion.
within 48 h from ACI onset, 21 (14%) had steal phenomenon
(median steal magnitude, 20%; interquartile range, 11%;
range, 6—45%), and 11 (7%) had RRHS. RRHS was most fre-
quent in patients with proximal arterial occlusions in the
anterior circulation (17% versus 1%; p < 0.001). Male gender,
younger age, persisting arterial occlusions, and excessive
sleepiness (evaluated by the Epworth Sleepiness Scale and
Berlin Questionnaire) were independently associated with
RRHS on multivariate logistic regression models [31].
Figure 4 Linear correlation of magnitude of steal phe-
nomenon as quantiﬁed on bilateral TCD-monitoring with net
perfusion deﬁcit as quantiﬁed on SPECT after Diamox-challenge
in patients who exhibited both steal phenomenon on TCD and
failed vasodilatory reserve on SPECT.
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The same group also sought to determine the potential
ssociation of RRHS with risk of early recurrent stroke. Their
ndings indicated that patients with acute anterior circula-
ion ischemic events and RRHS have a signiﬁcantly higher
isk of new ischemic stroke occurrence than acute stroke
atients without this condition [32]. This longitudinal asso-
iation persisted even after adjustment for demographic
haracteristics, vascular risk factors, and secondary preven-
ion therapies. They also observed that all recurrent strokes
n the RRHS subgroup occurred in the anterior circulation
ascular territory ipsilateral to the index event [32]. More-
ver the risk of recurrent stroke was front-loaded with a
our-fold increase being documented during the ﬁrst 30 days
f ictus [30-day stroke risk in RRHS(+) and RRHS(−) patients:
2% and 3%, respectively] [32]. These ﬁndings indicate that
he hemodynamic compromise caused by the vascular steal
henomenon may be an underlying mechanism linking large
essel atherosclerosis both with neurologic deterioration in
he acute stroke setting as well as with recurrent cerebral
schemia during the ﬁrst month after the index event.
otential therapeutic strategies of END caused by
ntracranial arterial steal phenomenon
n the ﬁrst documented cases of reversed Robin Hood
yndrome (RRHS), neurological worsening was also more
ronounced in patients with sleep apnea [27] or exces-
ive sleepiness [31]. Hence, patients with persisting arterial
cclusions and excessive sleepiness can be particularly vul-
erable to the steal. In the ﬁrst two reports describing
RHS no further END was observed in patients with intracra-
ial arterial steal that were treated with non-invasive
entilatory correction. [27,31] Moreover, early noninvasive
entilatory correction in AIS patients has been shown to be
afe and feasible in a recent pilot study [33]. In view of the
ormer considerations, it has been hypothesized that:
(i) RRHS may provide a missing link between the respiratory
status and END in ACI with history of obstructive sleep
apnea [34]
ii) and intracranial arterial steal phenomenon and sleep-
disordered breathing may represent linked therapeutic
targets [34].
erebral microembolization and END
CD can reliably detect in real-time asymptomatic microem-
olic signals (MESs) in cerebral circulation that are
haracterized as ‘‘High Intensity Transient Signals’’ (HITS)
35—39]. Asymptomatic cerebral embolization can be
etected by TCD in 7—71% of patients with ACI (Fig. 5)
35—39]. The prevalence of MES is highest in patients
ith large-artery atherosclerotic stroke with cardioembolic
nfarction being the second most common stroke subtype
ith concomitant asymptomatic microembolization. MES
re rarely identiﬁed in patients with lacunar stroke. The
umber of MES detected by TCD negatively correlates to
he elapsed time from symptom onset in patients with
CI [35—39]. In other words, the sooner TCD-monitoring
s performed from symptom onset the higher the yield of
ltrasound detection of MES.
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Figure 5 Detection of a microembolic signal in right MCA in a
patient with severe (>70%) extracranial carotid artery stenosis
during bilateral TCD-monitoring of MCAs. The ﬂow in right MCA
displays a characteristic ‘‘blunted’’ waveform appearance that
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ts indicative of a more proximal hemodynamically signiﬁcant
teno-occlusive lesion.
MES have been shown to predict recurrent stroke risk
n acute stroke, symptomatic carotid stenosis and postop-
ratively after CEA (Table 1) [35]. MES may also predict
rst-ever stroke risk in patients with asymptomatic carotid
tenosis (Table 1) [36]. More speciﬁcally, MES detection
y TCD-monitoring increases the risk of recurrent stroke
y almost ten-fold (OR: 9.6; 95%CI: 1.5—59.3) in patients
ith symptomatic carotid artery stenosis (Table 1). Simi-
arly, MES detection by TCD-monitoring increases the risk
f ipsilateral stroke by almost seven-fold (OR: 6.6; 95%CI:
.9—15.4) in patients with asymptomatic carotid artery
tenosis (Table 1). Consequently, MES have been used for
isk stratiﬁcation and assessment of therapeutic efﬁcacy in
he former conditions [35—37,39]. Hao et al. have recently
hown that MES have been associated with END and wors-
ning of neurological deﬁcit in patients with ACI due to
Table 1 Association of microembolic signals (MESs) detected by T
Patient subgroup N (studies/patients) Outcom
ACI (AIS/TIA) [35] 8/737 Rec. st
ACI (AIS/TIA) [35] 8/737 Rec. st
Sym. Car. Sten. [35] 4/270 Rec. st
Sym. Car. Sten. [35] 4/270 Rec. st
Asym. Car. Sten. [36] 6/1144 Ips. str
Asym. Car. Sten. [36] 6/1144 Ips. st.
Post-oper. CEA [35] 6/649 Rec. st
Post-oper. CEA [35] 6/649 Rec. st
ACI, acute cerebral ischemia; AIS, acute ischemic stroke; TIA, transient
Sten., carotid stenosis; Post-Oper. CEA, post-operative carotid endart
heterogeneity; and NS, non-signiﬁcant.
# p = 0.02.
¶ p = 0.002.
* p < 0.00001.
& p < 0.001.
$ p = 0.1.
@ p = 0.009.G. Tsivgoulis et al.
arge artery atherosclerosis [38]. Iguchi et al. have also
eported that the presence of MES at 48 h after symptom
nset was associated with recurrence of cerebral ischemia
n diffusion weighted imaging (DWI) independent of under-
ying stroke subtype, [40] while MES detection on baseline
CD-monitoring has been related to the presence of multiple
nfarction on baseline DWI [35,38].
otential therapeutic strategies of END caused by
erebral microembolization
wo small pilot randomized clinical trials have provided pre-
iminary evidence that clopidogrel load (300mg) followed by
ual antiplatelet therapy (combination of clopidogrel 75mg
nd aspirin 75—100mg for up to seven days following stroke
nset) may reduce substantially asymptomatic microem-
olization in patients with symptomatic extracranial carotid
rtery stenosis [CARESS (clopidogrel and aspirin for reduc-
ion of emboli in symptomatic carotid stenosis) trial] [41]
r symptomatic stenosis in cerebral or extracranial carotid
rteries [CLAIR (clopidogrel plus aspirin versus aspirin alone
or reducing embolization in patients with acute symp-
omatic cerebral or carotid artery stenosis) trial]. [42]
either CARESS nor CLAIR showed a beneﬁcial effect of
ual therapy in reducing the risk of recurrent stroke, but
hen both studies were combined there was an absolute
isk reduction of 6% (95% CI 1—11%) in recurrent stroke with
se of dual therapy (combination of aspirin and clopido-
rel) compared with aspirin monotherapy. [42] In view of
he former considerations, it may be postulated that:
(i) Continuous TCD-monitoring to detect the presence of
cerebral microembolization in real-time in patients
with large-artery atherosclerotic stroke may be indi-
cated.
(ii) Aggressive antiplatelet therapy (clopidogrel load fol-
lowed by combination antiplatelet therapy) may be
considered during the ﬁrst days of ictus in patients with
ACI due to large-artery atherosclerosis and detection of
MES on TCD-monitoring [43].
CD and risk of recurrent events in different clinical subgroups.
e event OR (95%CI) Heterogeneity (I2)
roke 2.4 (1.2—5.1)# 12% (NS)
roke/TIA 3.7 (1.6—8.4)¶ 47% (NS)
roke 9.6 (1.5—59.3)# 6% (NS)
roke/TIA 6.4 (2.9—13.4)* 0% (NS)
oke 6.6 (2.9—15.4)* 13% (NS)
/TIA 7.6 (2.3—24.7)& 73% (p = 0.002)
roke 2.5 (0.8—7.7)$ 0% (NS)
roke/TIA 3.6 (1.4—9.2)@ 0% (NS)
ischemic attack; Asym., asymptomatic; Sym., symptomatic; Car.
erectomy; Rec, recurrent; Ips., ipsilateral; St, stroke; Heter/ty,
ke
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(iii) Urgent carotid revascularization procedure (within
2weeks from symptom onset) should be performed in
patients with symptomatic extracranial carotid artery
stenosis independent of the presence of MES on TCD-
monitoring [44].
Conclusions
Numerous studies using different deﬁnitions have shown
that END is common in ACI and is associated with adverse
functional outcomes. The causes of END may be stratiﬁed
in two major groups: hemodynamic and non-hemodynamic.
The four main hemodynamic causes of END include: cardiac
complications, arterial reocclusion, intracranial arterial
steal phenomenon and cerebral microembolization. TCD
can reliably detect reocclusion in real-time offering us the
opportunity to pursue alternative reperfusion strategies.
Intracranial arterial steal/RRHS can also be detected by TCD
during voluntary breath-holding or using acetazolamide-
challenged perfusion CT or HMPAO SPECT. RRHS and
sleep-disordered breathing in ACI may represent linked ther-
apeutic targets that potentially could be managed using
non-invasive ventilatory correction. TCD can also reliably
detect in real-time MES in cerebral circulation that have
been independently associated with higher risk of recurrent
stroke in patients with ACI. Aggressive antiplatelet therapy
may be considered in patients with symptomatic carotid
stenosis and MES on TCD, while urgent carotid revascu-
larization procedure (within 2weeks from symptom onset)
should be performed in patients with symptomatic extracra-
nial carotid artery stenosis independent of the presence of
MES on TCD-monitoring.
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